# EDGAR Filing Document

**Accession Number:** 0001404123
**File Stem:** 0001562180-23-001845
**Filing Date:** 2023-2
**Character Count:** 13417
**Document Hash:** b8efcce687eaa915adcc3ace4b1c565e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001562180-23-001845.hdr.sgml**: 20230224

**ACCESSION NUMBER**: 0001562180-23-001845

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230222

**FILED AS OF DATE**: 20230224

**DATE AS OF CHANGE**: 20230224

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Auvil Paul R. III
- **CENTRAL INDEX KEY:** 0001410972

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39203
- **FILM NUMBER:** 23668813

**MAIL ADDRESS:**
- **STREET 1:** C/O PROOFPOINT, INC.
- **STREET 2:** 892 ROSS DRIVE
- **CITY:** SUNNYVALE
- **STATE:** CA
- **ZIP:** 94089
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 1Life Healthcare Inc
- **CENTRAL INDEX KEY:** 0001404123
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **IRS NUMBER:** 760707204
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** ONE EMBARCADERO CENTER, SUITE 1900
- **CITY:** San Francisco
- **STATE:** CA
- **ZIP:** 94111
- **BUSINESS PHONE:** (415) 814-0927

**MAIL ADDRESS:**
- **STREET 1:** ONE EMBARCADERO CENTER, SUITE 1900
- **CITY:** San Francisco
- **STATE:** CA
- **ZIP:** 94111

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 1life Healthcare Inc
- **DATE OF NAME CHANGE:** 20070621

## Ex-24

```

POWER OF ATTORNEY
      Know all by these presents, that the undersigned hereby
constitutes and appoints each of BJORN B. THALER, LISA A. MANGO, MATTHEW B.
HEMINGTON and IVY TSENG, signing individually, the undersigned's true and
lawful attorneys-in fact and agents to:
(1)	execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer, director or beneficial
owner of more than 10% of a registered class of securities of
1Life Healthcare, Inc. (the "Company"), Forms 3, 4 and 5
(including any amendments thereto) in accordance with Section
16(a) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act") and the rules thereunder and a Form ID, Uniform
Application for Access Codes to File on EDGAR;
(2)	do and perform any and all acts for and on behalf of the
undersigned that may be necessary or desirable to execute such
Forms 3, 4 or 5 or Form ID (including any amendments thereto)
and timely file such forms with the United States Securities and
Exchange Commission and any stock exchange or similar authority;
and
(3)	take any other action of any nature whatsoever in
connection with the foregoing which, in the opinion of such
attorney-in-fact, may be of benefit, in the best interest of, or
legally required by, the undersigned, it being understood that
the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such
form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's
discretion.
      The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all
intents and purposes as the undersigned might or could do if
personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or
such attorney-in-fact's substitute or substitutes, shall lawfully do
or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that
the foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Exchange Act.
      This Power of Attorney shall remain in full force and effect
until the earliest to occur of (a) the undersigned is no longer
required to file Forms 3, 4 and 5 with respect to the undersigned's
holdings of and transactions in securities issued by the Company, (b)
revocation by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact is no longer employed by
the Company or Cooley LLP.  The undersigned hereby acknowledges that
this Power of Attorney supersedes, revokes and terminates any power
of attorney executed by the undersigned prior to the date hereof for
the purposes listed above.
      IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of Date: February 1, 2021.

/s/ Paul R. Auvil
Paul R. Auvil

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Auvil Paul R. III<br><sub>(Last) (First) (Middle)</sub><br>C/O 1LIFE HEALTHCARE, INC.<br>ONE EMBARCADERO CENTER, SUITE 1900<br><sub>(Street)</sub><br>SAN FRANCISCO, CA 94111<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-22 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>1Life Healthcare Inc [ ONEM ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-02-22 |  | D |  | 12586.00 | D | 18.00<sup>(1)</sup> | 0.00 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Options (Right to buy) | $11.47 | 2023-02-22 |  | D |  |  | 10462.00 | <sup>(3)</sup> | 2029-09-18 | Common Stock | 10462.00 | <sup>(2)</sup> | 0.00 | D |  |
| Stock Option (Right to Buy) | $20.55 | 2023-02-22 |  | D |  |  | 984.00 | <sup>(5)</sup> | 2030-04-14 | Common Stock | 984.00 | <sup>(4)</sup> | 0.00 | D |  |
| Stock Option (Right to Buy) | $29.00 | 2023-02-22 |  | D |  |  | 5294.00 | <sup>(5)</sup> | 2030-05-13 | Common Stock | 5294.00 | <sup>(4)</sup> | 0.00 | D |  |
| Stock Option (Right to Buy) | $40.55 | 2023-02-22 |  | D |  |  | 498.00 | <sup>(5)</sup> | 2030-07-14 | Common Stock | 498.00 | <sup>(4)</sup> | 0.00 | D |  |
| Stock Option (Right to Buy) | $30.48 | 2023-02-22 |  | D |  |  | 1014.00 | <sup>(5)</sup> | 2030-10-14 | Common Stock | 1014.00 | <sup>(4)</sup> | 0.00 | D |  |
| Stock Option (Right to Buy) | $42.68 | 2023-02-22 |  | D |  |  | 725.00 | <sup>(5)</sup> | 2031-01-14 | Common Stock | 725.00 | <sup>(4)</sup> | 0.00 | D |  |
| Stock Option (Right to Buy) | $42.70 | 2023-02-22 |  | D |  |  | 718.00 | <sup>(5)</sup> | 2031-04-14 | Common Stock | 718.00 | <sup>(4)</sup> | 0.00 | D |  |
| Restricted Stock Units | <sup>(6)</sup> | 2023-02-22 |  | D |  |  | 20728.00 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 20728.00 | <sup>(7)</sup> | 0.00 | D |  |

---

### Footnotes:

(1) Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the
"Merger Agreement"), dated as of July 20, 2022, by and among Issuer, Amazon.com, Inc. ("Parent") and Negroni Merger Sub, Inc., a whollyowned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on
February 22, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of Issuercommon stock, par value $0.001 per share ("Shares") issued and outstanding immediately prior to the Effective Time was convertedautomatically into the right to receive $18.00 in cash, without interest (the "Merger Consideration").

(2) Pursuant to the Merger Agreement, at the Effective Time, each outstanding option ("Option") to purchase Shares granted under any of the Issuer's 2007 Equity Incentive Plan, 2017 Equity Incentive Plan, 2020 Equity Incentive Plan and the Iora Third Amended and Restated 2011 Equity Incentive Plan (collective, the "Issuer Stock Plans") or portion thereof that was vested or became vested as of the Effective Time, and had an exercise price per Share that is less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such Option and (ii) the aggregate number of Shares issuable upon exercise of such Option or portion thereof, subject to any required withholding of taxes.

(3) The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years, subject to reporting person's continuous service as of each such date. At the Effective Time, any unvested shares subject to the option were accelerated in full.

(4) Pursuant to the Merger Agreement, at the Effective Time, each Option, whether vested or unvested, that has an exercise price per
Share that is greater than the Merger Consideration was canceled without the payment of consideration.

(5) The shares subject to the option are fully vested and immediately exercisable.

(6) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. RSUs convert into theissuer's common stock on a one-for-one basis.

(7) The RSUs vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant. At the Effective Time, each outstanding RSU that was unvested was accelerated in full and was automatically converted in to the right to receive the Merger Consideration.

**Signature:** /s/ Ivy Tseng, Attorney-in-Fact for Paul R. Auvil  
**Date:** 2023-02-24

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**